ESLA vs EXOZ

Estrella Immunopharma, Inc. vs eXoZymes Inc. — Valuation Comparison 2026

ESLA

Biological Products, (No Diagnostic Substances)
Estrella Immunopharma, Inc.
Quality
3.1
out of 10
Value Trap
12
SAFE
Price
$1.09
Last close
Models
8/13
Active
VS

EXOZ

Biological Products, (No Diagnostic Substances)
eXoZymes Inc.
Quality
4.5
out of 10
Value Trap
Price
$9.85
Last close
Models
6/13
Active

Model-by-Model Comparison

ModelType ESLA Fair ValueESLA Upside EXOZ Fair ValueEXOZ Upside
Bayesian DCF Intrinsic $0.32 -70.3% $2.50 -74.6%
First Chicago Scenario $•••.•• ••.•% $•••.•• ••.•%
Markov DDM Intrinsic $•••.•• ••.•% $•••.•• ••.•%
ML-RIV Intrinsic $•••.•• ••.•% $•••.•• ••.•%
Dynamic NAV Asset-Based $0.29 -97.1%
PWERM Option-Based $•••.•• ••.•% $•••.•• ••.•%
Sentiment SOTP Hybrid $•••.•• ••.•% $•••.•• ••.•%
CUCE Ensemble Ensemble $•••.•• ••.•% $•••.•• ••.•%
RCMH-DCF Intrinsic $1.51 +35.0%
🔒

Unlock Full 13-Model Comparison

Access all valuation models for ESLA vs EXOZ — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

ESLA vs EXOZ — Which Stock Is More Undervalued?

EXOZ scores higher with a 4.5/10 quality rating vs ESLA's 3.1/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing Estrella Immunopharma, Inc. (ESLA) and eXoZymes Inc. (EXOZ) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

ESLA currently trades at $1.09 with a QOC of 3.1/10, while EXOZ trades at $9.85 with a QOC of 4.5/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).